Alkeus Pharma

Alkeus Pharma is a cutting-edge pharmaceutical brand that is dedicated to addressing the root cause of Stargardt Disease, one of the most common genetic causes of blindness in children and young adults. With more than 30,000 people in the United States affected by Stargardt Disease and no current treatment available, Alkeus Pharma is committed to transforming lives. Their groundbreaking product, Gildeuretinol (ALK-001), has earned the prestigious Breakthrough Therapy Designation from the U.

S. FDA. It is the first and only medicine in clinical development that selectively targets the underlying mechanism of Stargardt Disease, reducing the rate of vitamin A dimerization in the eye.

By avoiding toxic by-products that damage the retina, Gildeuretinol has shown significant potential in preserving visual function in animal models and clinical trials. In addition to Stargardt Disease, Alkeus Pharma is also exploring the use of Gildeuretinol in the treatment of Geographic Atrophy, an advanced form of dry age-related macular degeneration. With their commitment to innovation and groundbreaking research, Alkeus Pharma is poised to transform the field of eye disease treatment and bring hope to millions worldwide